Suppr超能文献

疟原虫氯喹抗性转运蛋白(Pfcrt)突变单倍型可能与氯喹耐药性不相关。

Pfcrt mutant haplotypes may not correspond with chloroquine resistance.

作者信息

Goswami Diganta, Dhiman Sunil, Rabha Bipul, Kumar Dinesh, Baruah Indra, Sharma Dhirendra Kumar, Veer Vijay

机构信息

Defence Research Laboratory, Tezpur, Assam, India.

出版信息

J Infect Dev Ctries. 2014 Jun 11;8(6):768-73. doi: 10.3855/jidc.3398.

Abstract

INTRODUCTION

Chloroquine resistance in Plasmodium falciparum is associated with mutations in pfcrt and pfmdr1 genes. The frequency distribution of pfcrt K76T and pfmdr1 N86Y mutations and their association with chloroquine susceptibility was studied in an endemic area along the Indo-Bangladesh border.

METHODOLOGY

A single-arm prospective study of clinical and parasitological responses in P. falciparum malaria patients to chloroquine was conducted in vivo. PCR-RFLP assay was used to detect pfcrt K76T and pfmdr1 N86Y mutations in P. falciparum. The PCR products of pfcrt gene were sequenced,  translated and aligned for haplotyping.

RESULTS

Out of 63 cases, 44 (69.8%) responded adequately to chloroquine treatment. Pfcrt K76T mutation was recorded in 100% of the treatment failure cases, whereas pfmdr1 N86Y mutation was found in 52.6% of the cases only. Early treatment failure (84.2%) occurred more frequently than late treatment failure (15.8%). Kaplan-Meier survival analysis showed that the probability estimate for treatment success after 7 and 15 days was 0.84 (95% CI = 0.72-0.92) and 0.70 (95% CI = 0.57-0.80), respectively. Sequence analysis of 72 to 76 pfcrt gene codons revealed the presence of two mutant (CVMNT, CVIET) and two wild (CVMNK, CVIEK) haplotypes. The mutant CVIET haplotype was predominantly distributed (42.1%).

CONCLUSIONS

The presence of mutations in pfcrt K76T and pfmdr1 N86Y genes is not sufficient to explain the therapeutic efficacy of chloroquine to P. falciparum. Study suggests that pfcrt K76T mutant haplotypes are widely distributed and are spreading diligently, which needs to be taken into account in devising an antimalarial policy.

摘要

引言

恶性疟原虫对氯喹的耐药性与pfcrt和pfmdr1基因的突变有关。在印度 - 孟加拉国边境的一个流行地区,研究了pfcrt K76T和pfmdr1 N86Y突变的频率分布及其与氯喹敏感性的关系。

方法

对恶性疟原虫疟疾患者对氯喹的临床和寄生虫学反应进行了一项单臂前瞻性体内研究。采用PCR-RFLP分析法检测恶性疟原虫中的pfcrt K76T和pfmdr1 N86Y突变。对pfcrt基因的PCR产物进行测序、翻译和比对以进行单倍型分析。

结果

63例患者中,44例(69.8%)对氯喹治疗反应良好。在100%的治疗失败病例中记录到pfcrt K76T突变,而仅在52.6%的病例中发现pfmdr1 N86Y突变。早期治疗失败(84.2%)比晚期治疗失败(15.8%)更频繁发生。Kaplan-Meier生存分析显示,7天和15天后治疗成功的概率估计分别为0.84(95%CI = 0.72 - 0.92)和0.70(95%CI = 0.57 - 0.80)。对72至76个pfcrt基因密码子的序列分析显示存在两种突变(CVMNT、CVIET)和两种野生(CVMNK、CVIEK)单倍型。突变型CVIET单倍型分布占主导(42.1%)。

结论

pfcrt K76T和pfmdr1 N86Y基因中的突变不足以解释氯喹对恶性疟原虫的治疗效果。研究表明,pfcrt K76T突变型单倍型广泛分布且正在迅速传播,在制定抗疟政策时需要考虑到这一点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验